Nature Medicine @NatureMedicine · 31 Aug 2026
As presented at the 2026 #ESCCongress: A secondary analysis of the CARDIOTTRansform trial revealed that eplontersen benefited patients with transthyretin amyloid cardiomyopathy who were not on stabilizers, but not those who were. https://t.co/MRGQqHPH1o
9 816Views
4Likes
3Reposts
0Replies
0Quotes
1Bookmarks
Is that a lot?
1.26×vs this author's median7 802 views is typical
62Percentile for this authorof 8 recent posts
1.10×vs 100K–1M median8 935 views is typical
2.74%Reachviews ÷ followers
0.07%Engagement rateof viewers reacted